Company intelligence / Profile preview

Padarn Therapeutics

Dover, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Padarn Therapeutics develops small-molecule inhibitors of CDK2 (and related CDK2/cyclin E1 and CDK1/cyclin A2 complexes) for cancer, with activity described in patent applications and trade press; no clinical-stage assets or trials are publicly reported as of the latest data.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

i2020 Accelerator / Torrey Pines Investment (formation and funding partner)OrbiMed (co-investor at formation via Loch group funding)BioGeneration Ventures (BGV) (co-investor at Loch group level)Molsoft (AI and computer-aided drug design support via Loch platform)ChemDiv (chemistry and CADD support via Loch platform)

Beyond the preview

Go deeper on Padarn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Padarn Therapeutics.

Explore the full profile